Dr. Pan is a co-founder of Connect and has served as President and Chairman of the Board of Directors since May 2012. He has over 25 years of experience in biopharmaceutical R&D, including 10 years in Europe and North America. Prior to co-founding Connect, Dr. Pan co-founded and led Crown Bioscience Inc., a U.S. venture-backed company … Read more
Dr. Chen is a Principal of Qiming Venture Partners, focusing on healthcare investment. Before joining Qiming Venture Partners, Dr. Chen was a senior scientist at Johnson & Johnson, where he focused on cancer medicine. Prior to that, Dr. Chen was a group leader at Jiangsu Hengrui Medicine, where he specialized in cancer immunotherapies. Dr. Chen … Read more
Dr. DiRocco is a principal at RA Capital Management. He works on both public and private investments and serves on the boards of directors for 89Bio, Inc., Achilles Therapeutics Ltd., CANbridge Pharmaceuticals Inc. and iTeos Therapeutics, Inc. Previously, Dr. DiRocco covered solid tumor oncology landscapes. He holds a B.A. in Biology from College of the … Read more
Ms Liu is a senior executive with more than 25 years of biopharmaceutical and legal firm experience and currently Executive Vice President, Legal Affairs, General Counsel and Secretary of Seagen Inc., a targeted cancer therapeutic company. She previously served in senior legal leadership roles at Halozyme Therapeutics, Inc. and Durect Corporation, including General Counsel, Head … Read more
Dr. Zheng has served as CEO and a member of our board of directors since he co-founded the company in 2012. He has over 25 years of biopharmaceutical industry experience in the autoimmune disease and inflammation therapeutic areas. Prior to co-founding Connect, Dr. Zheng was Director of Immunology at Arena Pharmaceuticals where he oversaw its … Read more
Ms. Wilson is a strategic biopharmaceutical finance executive and board member with more than 30 years of industry and leadership experience in life science companies across finance, strategy and risk management. She is currently an independent Director and Chairperson of the Audit Committee for Elicio Therapeutics (ELTX) (formerly Angion Biomedica) and LAVA Therapeutics (LVTX). She … Read more
Dr. Xanthopoulos has over 24 years of experience in the biotechnology and pharmaceutical research industries as an executive, company founder, chief executive officer, investor and board member. Dr. Xanthopoulos is currently Chairman & CEO of Shoreline Biosciences, and Chairman of Stork Capital Life Sciences, which focuses on building and investing in innovative biotechnology companies. He … Read more